Skip to main content
. 2021 Sep 24;12:759267. doi: 10.3389/fphar.2021.759267

FIGURE 4.

FIGURE 4

LINC01001 interacts with IGF2BP2. (A) Subcellular fractionation evaluated the localization of LINC01001 in crizotinib-resistant NSCLC cells. **p < 0.01, ***p < 0.001 vs Cytoplasm (B) Bioinformatics analysis indicated LINC01001 interacted with IGF2BP2. (C) RIP assay evaluated the interaction between LINC01001 and IGF2BP2 in drug resistant cells. ***p < 0.001 vs IgG group (D) RNA pulldown assay confirmed the interaction between LINC01001 and IGF2BP2. ***p < 0.001 vs Bio-NC group (E) RT-qPCR was conducted to assess the level of IGF2BP2 in crizotinib-resistance NSCLC cells. ***p < 0.001 vs WT group. Error bars represent SD. Data represent three independent experiments.